21.77-0.09-0.41%
After-market 06:30:40 PM EDT 8/9/2024BTT
Plus500. 82% of retail CFD accounts lose money
21.86-4.13-15.89%
Official Close 03:59:59 PM EDT 8/9/2024BTT
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
Best Online Brokers for Stock TradingWant to trade stocks and other assets? Don't lose hundreds of dollars in avoidable transaction costs! Discover the best brokers for stock trading and ordering other assets!
On Friday 08/09/2024 the closing price of the Cassava Sciences share was $21.86 on BTT.Compared to the opening price on Friday 08/09/2024 on BTT of $25.64, this is a drop of 17.29%.Cassava Sciences's market capitalization is $1.45 B by 47.98 M shares outstanding.
Is Cassava Sciences stock a Buy, Sell or Hold?
Cassava Sciences stock has received a consensus rating of buy. The average rating score is and is based on 7 buy ratings, 0 hold ratings, and 0 sell ratings.What was the 52-week low for Cassava Sciences stock?
The low in the last 52 weeks of Cassava Sciences stock was 8.38. According to the current price, Cassava Sciences is 259.79% away from the 52-week low.What was the 52-week high for Cassava Sciences stock?
The high in the last 52 weeks of Cassava Sciences stock was 42.11. According to the current price, Cassava Sciences is 51.70% away from the 52-week high.What are analysts forecasts for Cassava Sciences stock?
The 7 analysts offering price forecasts for Cassava Sciences have a median target of 125.00, with a high estimate of 131.00 and a low estimate of 124.00. The median estimate represents a 17.42 difference from the last price of 21.77.Cassava Sciences Stock Snapshot
21.85
Bid
38.00
Bid Size
21.95
Ask
500.00
Ask Size
8/9/2024
Date
6:30 PM
Time
143,635.00
Volume
21.86
Prev. Close
25.64
Open
47.98 M
Number of Shares
21.63
Day Low
27.14
Day High
21.77
8.38
52 Week Low
42.11
52 Week High
21.77
0.00
Dividend Yield
93.76
Free Float in %
-2.32
EPS in USD
3.25
Book Value per Share in USD
-1.96
Cash Flow per Share in USD
Cassava Sciences NewsMore News
TipRanks
JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)
InvestorPlace
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
GlobeNewswire
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
Seeking Alpha
Cassava Sciences GAAP EPS of $0.13
Historical Prices for Cassava Sciences
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Cassava Sciences Analyst Data
Total Analysts: 7
Buy Ratings: 7 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 124.00 Median: 125.00 Highest: 131.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Cassava Sciences Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/19/24 | H.C. Wainwright & Co. | Maintained Hold | neutral | |||
| 07/01/24 | H.C. Wainwright & Co. | Downgraded to Hold | neutral | |||
| 05/17/24 | H.C. Wainwright & Co. | Maintained Buy | $131 | gut | ||
| 03/05/24 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 08/08/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 07/06/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 05/09/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 03/06/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 01/24/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut |
Cassava Sciences Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 0 | 100 | 0 | 2 | 72 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -0.80 | -0.09 | -2.09 | -1.48 | 0.26 |
| P/E Ratio | -27.21 | -256.12 | -10.42 | -14.71 | 83.73 |
| EBIT | -117 | -21 | -121 | -111 | -34 |
| EBITDA | - | - | - | - | - |
| Net Profit | -23 | -4 | -112 | -81 | 15 |
| Net Profit Adjusted | -86 | 85 | - | - | - |
| Pre-Tax Profit | -27 | 9 | -112 | -102 | 19 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | -0.23 | -1.80 | -2.09 | -1.48 | 0.26 |
| Gross Income | - | 200 | - | - | - |
| Cash Flow from Investing | - | - | - | - | - |
| Cash Flow from Operations | - | - | - | - | - |
| Cash Flow from Financing | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | - | - | - | - | - |
| Research & Development Exp. | 72 | 93 | 71 | 61 | 43 |
| Capital Expenditure | - | - | - | - | - |
| Selling, General & Admin. Exp. | 59 | 33 | 50 | 52 | 53 |
| Shareholder’s Equity | - | - | - | - | - |
| Total Assets | - | - | - | - | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 3 | 3 | 3 | 2 |
| Average Estimate | - | -0.427 USD | -0.470 USD | -0.800 USD | -0.085 USD |
| Year Ago | - | -0.611 USD | -0.496 USD | -2.318 USD | - |
| Publish Date | - | 11/5/2024 | 3/4/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 3 | 3 | 3 | 2 |
| Average Estimate | - | 0 USD | 0 USD | 0 USD | 100 USD |
| Year Ago | - | 0 USD | 0 USD | 0 USD | - |
| Publish Date | - | 11/5/2024 | 3/4/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change of sales in % | - | - | - | - | - | - | - |
| Gross profit on sales | -1.53 | -1.30 | -0.53 | -0.02 | -0.06 | -0.07 | -0.07 |
| Gross profit on sales change in % | -17.60 | -143.63 | -2,327.27 | 62.07 | 15.94 | -1.47 | -17.24 |
| Operating income | -105.96 | -80.92 | -36.77 | -11.03 | -9.69 | -6.66 | -11.95 |
| Operating income change in % | -30.94 | -120.08 | -233.32 | -13.86 | -45.42 | 44.25 | 20.11 |
| Income before tax | -97.22 | -76.25 | -32.39 | -6.33 | -4.63 | -6.56 | -11.91 |
| Income before tax change in % | -27.50 | -135.44 | -411.29 | -36.77 | 29.37 | 44.95 | 19.79 |
| Income after tax | -97.22 | -76.25 | -32.39 | -6.33 | -4.63 | -6.56 | -11.91 |
| Income after tax change in % | -27.50 | -135.44 | -411.29 | -36.77 | 29.37 | 44.95 | 19.79 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 14.20 | 7.30 | 12.87 | 2.10 | 1.39 | 0.51 | 1.13 |
| Long-term liabilities per share | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Equity | 137.47 | 227.54 | 253.92 | 92.20 | 22.10 | 19.63 | 9.70 |
| Equity change in % | -39.58 | -10.39 | 175.40 | 317.21 | 12.59 | 102.37 | -47.96 |
| Balance sheet total | 151.66 | 234.83 | 266.78 | 94.30 | 23.49 | 20.14 | 10.83 |
| Balance sheet total change in % | -35.42 | -11.98 | 182.91 | 301.52 | 16.62 | 85.94 | -43.89 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 90.64 | 96.89 | 95.18 | 97.77 | 94.09 | 97.46 | 89.55 |
| Debt ratio in % | 9.36 | 3.11 | 4.82 | 2.23 | 5.91 | 2.54 | 10.45 |
Cassava Sciences Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| ROBERTSON SANFORD | 04/25/2024 | 69,000.00 | 955,851.00 | 22.00 | Buy | No |
| Barry Richard | 04/22/2024 | 176,085.00 | 469,562.00 | 22.00 | Buy | No |
| Kupiec James William | 04/17/2024 | 1,500.00 | 4,000.00 | 22.00 | Buy | No |
| Schoen Eric | 04/16/2024 | 1,500.00 | 21,300.00 | 22.00 | Buy | No |
| ROBERTSON SANFORD | 08/22/2023 | 30,000.00 | 886,851.00 | 17.45 | Buy | No |
| Barry Richard | 08/21/2023 | 16,571.00 | 293,477.00 | 16.65 | Buy | No |
| Barry Richard | 08/20/2023 | 1,906.00 | 276,906.00 | 16.80 | Buy | No |
| SCANNON PATRICK J MD PHD | 06/11/2023 | 1,000.00 | 1,000.00 | 0.95 | Buy | No |
| BARBIER REMI | 05/23/2023 | 9,545.00 | 380,852.00 | 25.25 | Sell | No |
| BARBIER REMI | 05/23/2023 | 47,723.00 | 734,279.00 | 25.25 | Sell | No |
| BARBIER REMI | 05/23/2023 | 71,428.00 | 782,002.00 | 16.87 | Buy | No |
| BARBIER REMI | 05/23/2023 | 14,285.00 | 390,397.00 | 16.87 | Buy | No |
| ROBERTSON SANFORD | 05/09/2023 | 2,142.00 | 856,851.00 | 16.66 | Buy | No |
| ROBERTSON SANFORD | 05/09/2023 | 3,571.00 | 854,709.00 | 16.66 | Buy | No |
| ROBERTSON SANFORD | 05/09/2023 | 3,571.00 | 851,138.00 | 19.60 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 2,142.00 | 10,552.00 | 16.66 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 3,571.00 | 17,694.00 | 19.60 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 3,571.00 | 14,123.00 | 16.66 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 7,077.00 | 10,617.00 | 23.34 | Buy | No |
| O DONNELL MICHAEL J | 03/06/2023 | 2,778.00 | 6,873.00 | 25.20 | Sell | No |
| O DONNELL MICHAEL J | 03/06/2023 | 2,361.00 | 9,651.00 | 25.20 | Sell | No |
| O DONNELL MICHAEL J | 03/06/2023 | 3,571.00 | 12,012.00 | 19.60 | Buy | No |
| O DONNELL MICHAEL J | 03/06/2023 | 3,571.00 | 8,441.00 | 16.66 | Buy | No |
| Barry Richard | 03/06/2023 | 77,276.00 | 275,000.00 | 25.76 | Buy | No |
| Barry Richard | 03/05/2023 | 11,565.00 | 197,724.00 | 26.13 | Buy | No |
Cassava Sciences Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2022 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2021 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2020 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2019 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2018 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2017 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2016 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2015 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2014 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2013 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2012 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2011 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2010 | Cassava Sciences | 14.00 | 29.63 | USD |
| 2009 | Cassava Sciences | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Cassava Sciences Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.427 USD | Q3 2024 Earnings Release | 11/05/2024 |
| Earnings Report | -0.470 USD | Q4 2024 Earnings Release | 03/04/2025 |
| Earnings Report | - | Q1 2025 Earnings Release | 05/05/2025 |
| Earnings Report | - | Q2 2025 Earnings Release | 07/30/2025 |
Cassava Sciences Past Events
| Event | Actual EPS | Info | Date |
|---|
Cassava Sciences Profile
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Cassava Sciences Shareholder
| Owner | in % |
|---|---|
| Freefloat | 93.76 |
| The Vanguard Group, Inc. | 4.85 |
| Vanguard Group, Inc. (Subfiler) | 4.67 |
| BlackRock Fund Advisors | 3.26 |
| Vanguard Total Stock Market ETF | 3.02 |
| Remi Barbier | 2.79 |
| BlackRock Institutional Trust Co. NA | 2.44 |
| Estate Of Sanford R Robertson | 2.37 |
| State Street Corp. | 2.28 |
| Geode Capital Management LLC | 2.02 |
| Vanguard Extended Market Index Fund | 1.45 |
| Gallacher Capital Management LLC | 1.21 |
| Cowen & Co. LLC | 1.04 |
| Richard Jon Barry | 0.98 |
| Fidelity Small Cap Index Fund | 0.84 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
